ClinicalTrials.gg
CompletedNCT00384930Updated Sep 2, 2009Results posted

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

A Phase 2/3 interventional study of tadalafil and tadalafil in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2009-09-02.

Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,058
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
Largest of 26
1,058 · median 258
Started
2006
with 1 other
Phase 2/3
Only one
of the 26
Registered
1st of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one has the largest enrollment, is one of 2 that started in 2006, is the only one in phase 2/3, and was the 1st registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including lower urinary tract symptoms.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, 45 years or older, with benign prostatic hyperplasia, including lower urinary tract symptoms for at least 6 months prior to Visit 1 and an International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 2.
  • Agree not to use approved or experimental benign prostatic hyperplasia or erectile dysfunction treatments anytime during the study
  • Have not taken finasteride or dutasteride therapy, any other lower urinary tract symptom (LUTS) therapy or phosphodiesterase type 5 (PDE5) inhibitors for specified duration of time prior to Visit 2.
  • Have a prostate specific antigen (PSA) score within acceptable range defined for study or negative of the prostate for cancer within 12 months of Visit 1.

Exclusion criteria

Exclusion Criteria:

  • History of urinary retention or lower urinary tract (bladder) stones 6 months before the start of the study
  • History of bladder outlet obstruction or urethral obstruction due to stricture, valves, sclerosis, or tumor.
  • History of cardiac conditions including angina requiring certain treatment with nitrates, heart disease or coronary conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for a specified time before starting the study.
  • Certain neurological conditions associated with bladder problems or injuries to the brain or spinal cord within a specified time before starting the study.
  • Nitrate use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,058 participants (actual)

Study arms

  • Placebo comparator
    1

    placebo tablet

    Drug: placebo

  • Active comparator
    2

    2.5 mg tadalafil tablet

    Drug: tadalafil

  • Active comparator
    3

    5 mg tadalafil tablet

    Drug: tadalafil

  • Active comparator
    4

    10 mg tadalafil tablet

    Drug: tadalafil

  • Active comparator
    5

    20 mg tadalafil tablet

    Drug: tadalafil

Interventions

  • 2.5 mg tadalafil tablet by mouth once a day for twelve weeks.

    Also known as: LY450190, Cialis, IC351

  • 5 mg tadalafil tablet by mouth once a day for twelve weeks.

    Also known as: LY450190, Cialis, IC351

  • 10 mg tadalafil tablet by mouth once a day for twelve weeks.

    Also known as: LY450190, Cialis, IC351

  • 20 mg tadalafil tablet by mouth once a day for twelve weeks.

    Also known as: LY450190, Cialis, IC351

  • Drugplacebo

    Placebo tablet taken by mouth one a day for twelve weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis

    Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.

    Time frame: Baseline and 12 weeks

  2. Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis

    Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) (Irritative) Subscore

    Measures irritative symptoms over the past 4 weeks of the IPSS. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 1 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.

    Time frame: baseline and 12 weeks

  2. Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore

    Measures obstructive symptoms over the past 4 weeks of the IPSS. IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 1 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.

    Time frame: 12 weeks

  3. Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Question 7 (Nocturia)

    Measures nocturia (the need to get up at night to urinate) over the past 4 weeks. Scores range from 1 (few episodes of nocturia) to 5 (frequent episodes of nocturia).

    Time frame: baseline and 12 weeks

  4. Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index

    Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).

    Time frame: baseline and 12 weeks

  5. Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BII)

    Measures the impact that symptoms of BPH has on the patients well being. This questionnaire has 4 questions assessing the level of urinary discomfort and it's impact on the patients. Three questions range from 0 (no impact) to 4 (high impact); one question ranges from 0 (low impact) to 4 (high impact). The BII score ranges from 0 to 16.

    Time frame: baseline and 12 weeks

  6. Number of Participants Who Answer "Yes" to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)

    LUTS-GAQ Question asks the participant if the treatment they have been on has improved their uninary symptoms.

    Time frame: 12 weeks

  7. Change From Baseline to 12 Week Endpoint in Peak Urinary Flow

    Measures the maximum flow rate of urine (measured in mL/s). This is a continuous parameter with positive numeric values.

    Time frame: baseline and 12 weeks

  8. Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) EF Domain

    Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.

    Time frame: baseline and 12 weeks

07

Results

Posted Aug 19, 2009

Participant flow

Participant flow — Overall Study
MilestonePlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Started212209212216209
Received double-blind study drug211208212216209
Completed185182182175162
Not completed2727304147
Withdrew: Adverse event54121114
Withdrew: Entry criteria not met26784
Withdrew: Lack of efficacy11212
Withdrew: Lost to follow-up53046
Withdrew: Physician decision01101
Withdrew: Protocol violation10164
Withdrew: Sponsor decision34050
Withdrew: Withdrawal by subject977616
Withdrew: Didn't receive double-blind study drug11000

Outcome measures

PrimaryChange From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis

Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis
units on a scalePlacebo5 mg Tadalafil
Baseline17.08 ± 6.3617.30 ± 5.97
Change from Baseline-2.25 ± 6.17-4.92 ± 5.67
Statistical analysis
  • Placebo vs 5 mg Tadalafil · Permutation Test · p = <0.001 (P-value for Change from Baseline. Change = Endpoint minus Baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) (Irritative) Subscore

Measures irritative symptoms over the past 4 weeks of the IPSS. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 1 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.

Time frame:
baseline and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) (Irritative) Subscore
units on a scalePlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Baseline7.58 ± 3.097.78 ± 2.867.65 ± 2.847.88 ± 2.677.53 ± 3.07
Change from Baseline-0.99 ± 2.92-1.62 ± 2.83-1.91 ± 2.64-2.04 ± 2.75-2.05 ± 2.86
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.025 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.57 · 95% CI -1.08 to -0.07Mean Difference = 2.5 mg Tadalafil minus Placebo
  • Placebo vs 5 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.90 · 95% CI -1.40 to -0.40Mean Difference = 5 mg Tadalafil minus Placebo
  • Placebo vs 10 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.96 · 95% CI -1.45 to -0.46Mean Difference = 10 mg Tadalafil minus Placebo
  • Placebo vs 20 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -1.07 · 95% CI -1.58 to -0.57Mean Difference = 20 mg Tadalafil minus Placebo
SecondaryChange From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore

Measures obstructive symptoms over the past 4 weeks of the IPSS. IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 1 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore
units on a scalePlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Baseline9.51 ± 4.219.71 ± 4.169.65 ± 4.109.88 ± 3.879.57 ± 4.45
Change from Baseline-1.27 ± 4.00-2.31 ± 3.84-3.00 ± 3.87-3.29 ± 4.04-3.17 ± 4.02
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.008 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.97 · 95% CI -1.69 to -0.26Mean Difference = 2.5 mg Tadalafil minus Placebo
  • Placebo vs 5 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -1.69 · 95% CI -2.40 to -0.98Mean Difference = 5 mg Tadalafil minus Placebo
  • Placebo vs 10 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -1.89 · 95% CI -2.60 to -1.18Mean Difference = 10 mg Tadalafil minus Placebo
  • Placebo vs 20 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -1.87 · 95% CI -2.59 to -1.15Mean Difference = 20 mg Tadalafil minus Placebo
SecondaryChange From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Question 7 (Nocturia)

Measures nocturia (the need to get up at night to urinate) over the past 4 weeks. Scores range from 1 (few episodes of nocturia) to 5 (frequent episodes of nocturia).

Time frame:
baseline and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Question 7 (Nocturia)
units on a scalePlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Baseline2.36 ± 1.102.37 ± 1.312.36 ± 1.912.36 ± 1.152.20 ± 1.23
Change from Baseline-0.36 ± 1.09-0.43 ± 1.33-0.49 ± 1.17-0.43 ± 1.28-0.54 ± 1.17
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.503 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.07 · 95% CI -0.28 to 0.14Mean Difference = 2.5 mg Tadalafil minus Placebo
  • Placebo vs 5 mg Tadalafil · ANCOVA · p = 0.206 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.13 · 95% CI -0.34 to 0.07Mean Difference = 5 mg Tadalafil minus Placebo
  • Placebo vs 10 mg Tadalafil · ANCOVA · p = 0.452 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.08 · 95% CI -0.28 to 0.13Mean Difference = 10 mg Tadalafil minus Placebo
  • Placebo vs 20 mg Tadalafil · ANCOVA · p = 0.012 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.26 · 95% CI -0.47 to -0.06Mean Difference = 20 mg Tadalafil minus Placebo
SecondaryChange From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index

Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).

Time frame:
baseline and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index
units on a scalePlacebo2.5 mg Tadalafil5.0 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Baseline3.57 ± 1.193.69 ± 1.193.54 ± 1.303.55 ± 1.233.59 ± 1.28
Change from Baseline-0.56 ± 1.20-0.86 ± 1.13-0.92 ± 1.30-0.98 ± 1.46-0.97 ± 1.27
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.029 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.26 · 95% CI -0.49 to -0.03Mean Difference = 2.5 mg Tadalafil minus Placebo
  • Placebo vs 5.0 mg Tadalafil · ANCOVA · p = 0.002 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.37 · 95% CI -0.60 to -0.14Mean Difference = 5 mg Tadalafil minus Placebo
  • Placebo vs 10 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.43 · 95% CI -0.66 to -0.19Mean Difference = 10 mg Tadalafil minus Placebo
  • Placebo vs 20 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.40 · 95% CI -0.64 to -0.17Mean Difference = 20 mg Tadalafil minus Placebo
SecondaryChange From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BII)

Measures the impact that symptoms of BPH has on the patients well being. This questionnaire has 4 questions assessing the level of urinary discomfort and it's impact on the patients. Three questions range from 0 (no impact) to 4 (high impact); one question ranges from 0 (low impact) to 4 (high impact). The BII score ranges from 0 to 16.

Time frame:
baseline and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BII)
units on a scalePlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Baseline4.94 ± 2.954.73 ± 2.954.66 ± 2.984.86 ± 2.984.75 ± 2.79
Change from Baseline-0.79 ± 2.52-0.83 ± 2.66-1.25 ± 2.75-1.31 ± 2.79-1.34 ± 2.41
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.583 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.13 · 95% CI -0.58 to 0.33Mean Difference = 2.5 mg Tadalafil minus Placebo
  • Placebo vs 5 mg Tadalafil · ANCOVA · p = 0.013 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.57 · 95% CI -1.03 to -0.12Mean Difference = 5 mg Tadalafil minus Placebo
  • Placebo vs 10 mg Tadalafil · ANCOVA · p = 0.016 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.55 · 95% CI -1.00 to -0.10Mean Difference = 10 mg Tadalafil minus Placebo
  • Placebo vs 20 mg Tadalafil · ANCOVA · p = 0.007 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -0.62 · 95% CI -1.08 to -0.17Mean Difference = 20 mg Tadalafil minus Placebo
SecondaryNumber of Participants Who Answer "Yes" to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)

LUTS-GAQ Question asks the participant if the treatment they have been on has improved their uninary symptoms.

Time frame:
12 weeks
Reported as:
Number · participants
Number of Participants Who Answer "Yes" to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)
participantsPlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Number of Participants Who Answer "Yes" to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)109120139146138
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · Cochran-Mantel-Haenszel · p = 0.133 (P-values are from Cochran-Mantel-Haenszel test stratified by the randomization strata factors (4 geographic regions, 2 levels of IPSS severity, 2 levels of ED history) as fixed effect, and were not adjusted for multiple comparisons.)
  • Placebo vs 5 mg Tadalafil · Cochran-Mantel-Haenszel · p = 0.003 (P-values are from Cochran-Mantel-Haenszel test stratified by the randomization strata factors (4 geographic regions, 2 levels of IPSS severity, 2 levels of ED history) as fixed effect, and were not adjusted for multiple comparisons.)
  • Placebo vs 10 mg Tadalafil · Cochran-Mantel-Haenszel · p = <0.001 (P-values are from Cochran-Mantel-Haenszel test stratified by the randomization strata factors (4 geographic regions, 2 levels of IPSS severity, 2 levels of ED history) as fixed effect, and were not adjusted for multiple comparisons.)
  • Placebo vs 20 mg Tadalafil · Cochran-Mantel-Haenszel · p = <0.001 (P-values are from Cochran-Mantel-Haenszel test stratified by the randomization strata factors (4 geographic regions, 2 levels of IPSS severity, 2 levels of ED history) as fixed effect, and were not adjusted for multiple comparisons.)
SecondaryChange From Baseline to 12 Week Endpoint in Peak Urinary Flow

Measures the maximum flow rate of urine (measured in mL/s). This is a continuous parameter with positive numeric values.

Time frame:
baseline and 12 weeks
Reported as:
Mean · milliliter per second
Change From Baseline to 12 Week Endpoint in Peak Urinary Flow
milliliter per secondPlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Baseline10.31 ± 4.859.97 ± 4.0910.37 ± 3.869.93 ± 3.779.82 ± 3.97
Change from Baseline1.23 ± 5.011.50 ± 4.561.61 ± 3.951.69 ± 4.462.15 ± 4.69
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.735 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): 0.14 · 95% CI -0.69 to 0.98Mean Difference = 2.5 mg Tadalafil minus Placebo
  • Placebo vs 5 mg Tadalafil · ANCOVA · p = 0.355 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): 0.39 · 95% CI -0.44 to 1.23Mean Difference = 5 mg Tadalafil minus Placebo
  • Placebo vs 10 mg Tadalafil · ANCOVA · p = 0.433 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): 0.34 · 95% CI -0.50 to 1.17Mean Difference = 10 mg Tadalafil minus Placebo
  • Placebo vs 20 mg Tadalafil · ANCOVA · p = 0.089 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): 0.74 · 95% CI -0.11 to 1.59Mean Difference = 20 mg Tadalafil minus Placebo
SecondaryChange From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) EF Domain

Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.

Time frame:
baseline and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) EF Domain
units on a scalePlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Baseline17.26 ± 7.9517.42 ± 8.3015.29 ± 8.1317.22 ± 8.4316.28 ± 8.05
Change from Baseline0.78 ± 6.323.97 ± 7.306.56 ± 9.436.64 ± 8.297.44 ± 8.42
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): 3.36 · 95% CI 1.56 to 5.17Mean Difference = 2.5 mg Tadalafil minus Placebo
  • Placebo vs 5 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): 4.75 · 95% CI 2.95 to 6.54Mean Difference = 5 mg Tadalafil minus Placebo
  • Placebo vs 10 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): 5.83 · 95% CI 4.04 to 7.62Mean Difference = 10 mg Tadalafil minus Placebo
  • Placebo vs 20 mg Tadalafil · ANCOVA · p = <0.001 (P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): 6.15 · 95% CI 4.35 to 7.95Mean Difference = 20 mg Tadalafil minus Placebo
PrimaryChange From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis

Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis
units on a scalePlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis-2.23 ± 0.49-3.81 ± 0.50-4.83 ± 0.49-5.13 ± 0.48-5.17 ± 0.50
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.005 (P-values are from an ANCOVA model with effect of treatment group, geographic region, and IPSS baseline value (at Visit 3) as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -1.58 · 95% CI -2.68 to -0.48Mean Difference = 2.5 mg Tadalafil minus Placebo
  • Placebo vs 5 mg Tadalafil · ANCOVA · p = <0.001 (P-values are from an ANCOVA model with effect of treatment group, geographic region, and IPSS baseline value (at Visit 3) as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -2.60 · 95% CI -3.69 to -1.51Mean Difference = 5 mg Tadalafil minus Placebo
  • Placebo vs 10 mg Tadalafil · ANCOVA · p = <0.001 (P-values are from an ANCOVA model with effect of treatment group, geographic region, and IPSS baseline value (at Visit 3) as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -2.90 · 95% CI -3.99 to -1.81Mean Difference = 10 mg Tadalafil minus Placebo
  • Placebo vs 20 mg Tadalafil · ANCOVA · p = <0.001 (P-values are from an ANCOVA model with effect of treatment group, geographic region, and IPSS baseline value (at Visit 3) as a covariate, and were not adjusted for multiple comparisons.) · Mean difference (net): -2.94 · 95% CI -4.04 to -1.84Mean Difference = 20 mg Tadalafil minus Placebo

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo———
2.5 mg Tadalafil———
5 mg Tadalafil———
10 mg Tadalafil———
20 mg Tadalafil———
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Atrial tachycardiaCardiac disorders0/2121/2090/2120/2160/209
Myocardial infarctionCardiac disorders0/2121/2090/2120/2160/209
ArthritisMusculoskeletal and connective tissue disorders1/2120/2090/2121/2161/209
Back painMusculoskeletal and connective tissue disorders0/2120/2090/2120/2161/209
Bladder neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2121/2090/2120/2160/209
Cerebrovascular accidentNervous system disorders1/2120/2090/2120/2161/209
NephrolithiasisRenal and urinary disorders0/2121/2090/2120/2160/209
Renal failure acuteRenal and urinary disorders0/2121/2090/2120/2160/209
Ureteric ruptureRenal and urinary disorders0/2121/2090/2120/2160/209
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2120/2090/2120/2161/209
Most frequent other events
Showing 10 of 192
Most frequent other events
EventPlacebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg Tadalafil
Back painMusculoskeletal and connective tissue disorders1/2123/2092/21210/21611/209
HeadacheNervous system disorders6/2125/2096/21211/2167/209
DyspepsiaGastrointestinal disorders0/2122/20910/2126/21610/209
NasopharyngitisInfections and infestations2/2127/2094/2122/2165/209
MyalgiaMusculoskeletal and connective tissue disorders0/2123/2093/2126/2166/209
DiarrhoeaGastrointestinal disorders3/2122/2096/2121/2165/209
Gastrooesophageal reflux diseaseGastrointestinal disorders0/2122/2092/2126/2163/209
Muscle spasmsMusculoskeletal and connective tissue disorders0/2122/2090/2122/2165/209
Pain in extremityMusculoskeletal and connective tissue disorders0/2123/2095/2122/2163/209
BronchitisInfections and infestations1/2123/2091/2125/2160/209

Baseline characteristics

Age Continuous
Age Continuous(years)Placebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg TadalafilTotal
Mean61.75 ± 7.6962.03 ± 8.4261.95 ± 8.1762.22 ± 7.2062.55 ± 8.0962.10 ± 7.91
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg TadalafilTotal
Female000000
Male2112082122162091056
Region of Enrollment
Region of Enrollment(participants)Placebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg TadalafilTotal
Australia4556424
Canada125913645
France13129151160
Germany2935392833164
Greece8912111050
Italy151059948
Mexico191617191990
Spain3325417
Sweden4254520
United States105112109106108540
Baseline (Visit 3) Lower Urinary Tract Symptoms (LUTS) Severity
Baseline (Visit 3) Lower Urinary Tract Symptoms (LUTS) Severity(participants)Placebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg TadalafilTotal
Moderate (<20 units on a scale: IPSS)137139141143141701
Severe (>=20 units on a scale: IPSS)7469717268354
Unknown000101
Duration of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Duration of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)(participants)Placebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg TadalafilTotal
< 6 months000101
6 months to 1 year4427372739174
1 year to 3 years6264638170340
> 3 years105117112107100541
Erectile Dysfunction
Erectile Dysfunction(participants)Placebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg TadalafilTotal
Yes142135144150145716
No6771686461331
Unknown120238
Not Collected100001
Previous Therapy for Benign Prostatic Hyperplasia (BPH)
Previous Therapy for Benign Prostatic Hyperplasia (BPH)(participants)Placebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg TadalafilTotal
No153139158160152762
Yes5869545657294
Race/Ethnicity
Race/Ethnicity(participants)Placebo2.5 mg Tadalafil5 mg Tadalafil10 mg Tadalafil20 mg TadalafilTotal
African3375523
Caucasian179184179186176904
East Asian011002
Hispanic2920252425123
West Asian000134

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenwood, Indiana, United States
09

References and documents

Publications

  • Vlachopoulos C, Oelke M, Maggi M, Mulhall JP, Rosenberg MT, Brock GB, Esler A, Buttner H. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. Int J Clin Pract. 2015 Dec;69(12):1496-507. doi: 10.1111/ijcp.12722. Epub 2015 Aug 24. PubMed 26299520 ↗
  • Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology. 2010 Jun;75(6):1452-8. doi: 10.1016/j.urology.2009.09.093. Epub 2010 Feb 16. PubMed 20163842 ↗
  • Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009 Oct;56(4):727-35. doi: 10.1016/j.eururo.2009.04.033. Epub 2009 Apr 22. Erratum In: Eur Urol. 2011 Jun;59(6):1082. PubMed 19409693 ↗
  • Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008 Oct;180(4):1228-34. doi: 10.1016/j.juro.2008.06.079. Epub 2008 Aug 22. PubMed 18722631 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Oct 2007 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2006
First posted
Oct 6, 2006
Start
Aug 2006
Primary completionActual
Oct 2007
CompletionActual
Oct 2008
Results first posted
Aug 19, 2009
Last update
Sep 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00384930
Collaborators
ICOS Corporation
First posted
Oct 6, 2006
Start date
Aug 2006
Primary completion
Oct 2007
Completion
Oct 2008
Results posted
Aug 19, 2009
Last update
Sep 2, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion